A switch-on mechanism to activate maize ribosome-inactivating protein for targeting HIV-infected cells

Maize ribosome-inactivating protein (RIP) is a plant toxin that inactivates eukaryotic ribosomes by depurinating a specific adenine residue at the α-sarcin/ricin loop of 28S rRNA. Maize RIP is first produced as a proenzyme with a 25-amino acid internal inactivation region on the protein surface. During germination, proteolytic removal of this internal inactivation region generates the active heterodimeric maize RIP with full N-glycosidase activity. This naturally occurring switch-on mechanism provides an opportunity for targeting the cytotoxin to pathogen-infected cells. Here, we report the addition of HIV-1 protease recognition sequences to the internal inactivation region and the activation of the maize RIP variants by HIV-1 protease in vitro and in HIV-infected cells. Among the variants generated, two were cleaved efficiently by HIV-1 protease. The HIV-1 protease-activated variants showed enhanced N-glycosidase activity in vivo as compared to their un-activated counterparts. They also possessed potent inhibitory effect on p24 antigen production in human T cells infected by two HIV-1 strains. This switch-on strategy for activating the enzymatic activity of maize RIP in target cells provides a platform for combating pathogens with a specific protease.

[1]  P. Shaw,et al.  Solution structure of an active mutant of maize ribosome-inactivating protein (MOD) and its interaction with the ribosomal stalk protein P2. , 2010, Journal of molecular biology.

[2]  Diana M. Mitrea,et al.  Engineering an artificial zymogen by alternate frame protein folding , 2010, Proceedings of the National Academy of Sciences.

[3]  W. Tolleson,et al.  A functional quantitative polymerase chain reaction assay for ricin, Shiga toxin, and related ribosome-inactivating proteins. , 2010, Analytical biochemistry.

[4]  M. Kimmel,et al.  Conflict of interest statement. None declared. , 2010 .

[5]  Du Feng,et al.  Trichosanthin inhibits integration of human immunodeficiency virus type 1 through depurinating the long-terminal repeats , 2010, Molecular Biology Reports.

[6]  G. Zhu,et al.  The C-terminal fragment of the ribosomal P protein complexed to trichosanthin reveals the interaction between the ribosome-inactivating protein and the ribosome , 2008, Nucleic acids research.

[7]  Ji-Jun Chen,et al.  Anti-HIV-1 activities of compounds isolated from the medicinal plant Rhus chinensis. , 2008, Journal of ethnopharmacology.

[8]  P. Shaw,et al.  1H, 13C and 15N backbone and side chain resonance assignments of a 28 kDa active mutant of maize ribosome-inactivating protein (MOD) , 2007, Biomolecular NMR assignments.

[9]  M. Fabbrini,et al.  Lipopolyamine treatment increases the efficacy of intoxication with saporin and an anticancer saporin conjugate , 2007, The FEBS journal.

[10]  P. Shaw,et al.  Structure-function study of maize ribosome-inactivating protein: implications for the internal inactivation region and the sole glutamate in the active site , 2007, Nucleic acids research.

[11]  Steven Sheriff,et al.  X-Ray Crystal Structures of Human Immunodeficiency Virus Type 1 Protease Mutants Complexed with Atazanavir , 2007, Journal of Virology.

[12]  F. Stirpe,et al.  Ribosome-inactivating proteins: progress and problems , 2006, Cellular and Molecular Life Sciences CMLS.

[13]  A. Kaplan,et al.  Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates , 2005, Retrovirology.

[14]  J. Clemente,et al.  Ordered Processing of the Human Immunodeficiency Virus Type 1 GagPol Precursor Is Influenced by the Context of the Embedded Viral Protease , 2005, Journal of Virology.

[15]  P. Shaw,et al.  Recent advances in trichosanthin, a ribosome-inactivating protein with multiple pharmacological properties. , 2005, Toxicon : official journal of the International Society on Toxinology.

[16]  J. Tözsér,et al.  Amino Acid Preferences for a Critical Substrate Binding Subsite of Retroviral Proteases in Type 1 Cleavage Sites , 2005, Journal of Virology.

[17]  H. Bass,et al.  Maize ribosome-inactivating proteins (RIPs) with distinct expression patterns have similar requirements for proenzyme activation. , 2004, Journal of experimental botany.

[18]  A. Aigner,et al.  Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. , 2004, Biochemical and biophysical research communications.

[19]  Irene T Weber,et al.  Narrow Substrate Specificity and Sensitivity toward Ligand-binding Site Mutations of Human T-cell Leukemia Virus Type 1 Protease* , 2004, Journal of Biological Chemistry.

[20]  Celia A. Schiffer,et al.  Replacement of the P1 Amino Acid of Human Immunodeficiency Virus Type 1 Gag Processing Sites Can Inhibit or Enhance the Rate of Cleavage by the Viral Protease , 2002, Journal of Virology.

[21]  L. Citores,et al.  Targeting cancer cells with transferrin conjugates containing the non-toxic type 2 ribosome-inactivating proteins nigrin b or ebulin l. , 2002, Cancer letters.

[22]  Robert W. Shafer,et al.  Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance , 2002, Clinical Microbiology Reviews.

[23]  I. Heisler,et al.  A colorimetric assay for the quantitation of free adenine applied to determine the enzymatic activity of ribosome-inactivating proteins. , 2002, Analytical biochemistry.

[24]  P. Shaw,et al.  Trichosanthin interacts with acidic ribosomal proteins P0 and P1 and mitotic checkpoint protein MAD2B. , 2001, European journal of biochemistry.

[25]  J. Louis,et al.  Antiviral agent based on the non-structural protein targeting the maturation process of HIV-1: expression and susceptibility of chimeric Vpr as a substrate for cleavage by HIV-1 protease. , 2000, Protein engineering.

[26]  Y. Zheng,et al.  Anti-HIV-1 activity of trichobitacin, a novel ribosome-inactivating protein. , 2000, Acta pharmacologica Sinica.

[27]  F. Uckun,et al.  Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. , 1999, The Journal of pharmacology and experimental therapeutics.

[28]  F. Uckun,et al.  Pokeweed antiviral protein isoforms PAP-I, PAP-II, and PAP-III depurinate RNA of human immunodeficiency virus (HIV)-1. , 1999, Biochemical and biophysical research communications.

[29]  J. Dinman,et al.  Pokeweed Antiviral Protein Accesses Ribosomes by Binding to L3* , 1999, The Journal of Biological Chemistry.

[30]  Natalie A. Lissy,et al.  Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein , 1999, Nature Medicine.

[31]  H. Kräusslich,et al.  Sequential Steps in Human Immunodeficiency Virus Particle Maturation Revealed by Alterations of Individual Gag Polyprotein Cleavage Sites , 1998, Journal of Virology.

[32]  F. Uckun,et al.  TXU (Anti-CD7)-Pokeweed Antiviral Protein as a Potent Inhibitor of Human Immunodeficiency Virus , 1998, Antimicrobial Agents and Chemotherapy.

[33]  Eric A. Hendrickson,et al.  A Sequential Two-Step Mechanism for the Production of the Mature p17:p12 Form of Caspase-3 in Vitro * , 1997, The Journal of Biological Chemistry.

[34]  I. Weber,et al.  Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P. Chomczyński,et al.  Short technical reports. Modification of the TRI reagent procedure for isolation of RNA from polysaccharide- and proteoglycan-rich sources. , 1995, BioTechniques.

[36]  T. A. Walsh,et al.  Maize Ribosome-Inactivating Protein (b-32) (Homologs in Related Species, Effects on Maize Ribosomes, and Modulation of Activity by Pro-Peptide Deletions) , 1995, Plant physiology.

[37]  S. Lee-Huang,et al.  Human immunodeficiency virus type 1 (HIV-1) inhibition, DNA-binding, RNA-binding, and ribosome inactivation activities in the N-terminal segments of the plant anti-HIV protein GAP31. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Kahn,et al.  Safety, activity, and pharmacokinetics of GLQ223 in patients with AIDS and AIDS-related complex , 1994, Antimicrobial Agents and Chemotherapy.

[39]  J. Tang,et al.  Relationships of human immunodeficiency virus protease with eukaryotic aspartic proteases. , 1994, Methods in enzymology.

[40]  O. Ramilo,et al.  Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  T. A. Walsh,et al.  Characterization and molecular cloning of a proenzyme form of a ribosome-inactivating protein from maize. Novel mechanism of proenzyme activation by proteolytic removal of a 2.8-kilodalton internal peptide segment. , 1991, The Journal of biological chemistry.

[42]  S. Lee-Huang,et al.  A new class of anti‐HIV agents: GAP31, DAPs 30 and 32 , 1991, FEBS letters.

[43]  S. Lee-Huang,et al.  TAP 29: an anti-human immunodeficiency virus protein from Trichosanthes kirilowii that is nontoxic to intact cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[44]  T. Copeland,et al.  Comparison of the HIV‐1 and HIV‐2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag‐Pol polyproteins , 1991, FEBS letters.

[45]  E. Tschachler,et al.  Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin , 1990, The Journal of experimental medicine.

[46]  S. Zolla-Pazner,et al.  Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[47]  E. Wimmer,et al.  Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[48]  John,et al.  Purification and characterization of trichosanthin. Homology to the ricin A chain and implications as to mechanism of abortifacient activity. , 1987, The Journal of biological chemistry.

[49]  H. Yeung,et al.  The immunomodulatory and antitumor activities of trichosanthin-an abortifacient protein isolated from tian-hua-fen (Trichosanthes kirilowii). , 1986, Asian Pacific journal of allergy and immunology.

[50]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[51]  W. Watkins,et al.  Linkage‐specific α‐D‐galactosidases from Trichomonas foetus: Characterisation of the blood‐group B‐destroying enzyme as A 1,3‐α‐galactosidase and the blood‐group P1‐destroying enzyme as A 1,4‐α‐galactosidase , 1975 .

[52]  Luis Carrasco,et al.  Ribosome inactivation by the toxic lectins abrin and ricin. Kinetics of the enzymic activity of the toxin A-chains. , 1975, European journal of biochemistry.